Homoharringtonine Inhibits CVS-11 and Clinical Isolates of Rabies Virus In Vitro: Identified via High-Throughput Screening of an FDA-Approved Drug Library
Viruses · 2025
DOI: 10.3390/v17070945 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Kalenahalli Rajappa Harisha und 9 weiteren Autor:innen. Beteiligte Einrichtung: Foundation for Neglected Disease Research (FNDR), Bengaluru 561203, India. Hauptthemen laut MEDLINE: Antiviral Agents, Rabies virus, Homoharringtonine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Rabies, a viral encephalitis caused by rabies virus (RABV), is 100% fatal upon the onset of symptoms. Effective post-exposure prophylaxis (PEP) measures are available, but they are often difficult to access in low-income countries. WHO estimates about 59,000 deaths due to rabies globally, and the majority are contributed by developing countries. Hence, developing drugs for the treatment of post-symptomatic rabies is an urgent and unmet demand. It is worth noting that previous efforts regarding antiviral strategies, such as small-interfering RNA, antibodies and small-molecule inhibitors, against the rabies virus have failed to show efficacy in pre-clinical studies, especially when the virus has reached the central nervous system (CNS). Therefore, drug repurposing seems to be an alternative tool for the development of new anti-rabies drugs. We validated and used a high-throughput, FITC-conjugated antibody-based flow cytometry assay to expedite the identification of repurposable new drug candidates against the RABV. The assay was validated using ribavirin and salinomycin as reference compounds, which showed EC50 values of 10.08 µM and 0.07 µM, respectively. We screened a SelleckChem library comprising 3035 FDA-approved compounds against RABV (CVS-11) at 10 µM concentration. Five compounds (clofazimine, tiamulin, difloxacin, harringtonine and homoharringtonine) were active against RABV, with greater than 90% inhibition. Homoharringtonine (HHT) identified in the present study is active against laboratory-adapted RABV (CVS-11) and clinical isolates of RABV, with an average EC50 of 0.3 µM in both BHK-21 and Neuro-2a cell lines and exhibits post-entry inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Foundation for Neglected Disease Research (FNDR), Bengaluru 561203, India.
- Veterinary College, Karnataka Veterinary, Animal and Fisheries Sciences University (KVAFSU), Hebbal, Bengaluru 560024, India.
ORCID-Profile: Radha Krishan Shandil, Gudepalya Renukaiah Rudramurthy
Zitieren
APA
Harisha, K. R., Kailaje, V., Kondreddi, R. R., Gudla, C. S., Singh, S., Ramakrishnaiah, S., Isloor, S., Narayanan, S., Shandil, R. K., & Rudramurthy, G. R. (2025). Homoharringtonine Inhibits CVS-11 and Clinical Isolates of Rabies Virus In Vitro: Identified via High-Throughput Screening of an FDA-Approved Drug Library. Viruses. https://doi.org/10.3390/v17070945
Vancouver
Harisha KR, Kailaje V, Kondreddi RR, Gudla CS, Singh S, Ramakrishnaiah S, et al. Homoharringtonine Inhibits CVS-11 and Clinical Isolates of Rabies Virus In Vitro: Identified via High-Throughput Screening of an FDA-Approved Drug Library. Viruses. 2025. doi:10.3390/v17070945
BibTeX
@article{Harisha2025,
author = {Harisha, Kalenahalli Rajappa and Kailaje, Varun and Kondreddi, Ravinder Reddy and Gudla, Chandra Sekhar and Singh, Shraddha and Ramakrishnaiah, Sharada and Isloor, Shrikrishna and Narayanan, Shridhar and Shandil, Radha Krishan and Rudramurthy, Gudepalya Renukaiah},
title = {Homoharringtonine Inhibits CVS-11 and Clinical Isolates of Rabies Virus In Vitro: Identified via High-Throughput Screening of an FDA-Approved Drug Library},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17070945}
}
EUVIMED